GtoPdb Ligand ID: 6477

Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
mogamulizumab is an approved drug (PMDA (Japan, 2014), EMA & FDA (2018))
Compound class: Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Compound class Antibody
Approved drug? Yes (PMDA (Japan, 2014), EMA & FDA (2018))
International Nonproprietary Names
INN number INN
9374 mogamulizumab
KW-0761 | mogamulizumab-kpkc | Poteligeo®
Database Links
Specialist databases
IMGT/mAb-DB 366
Other databases
GtoPdb PubChem SID 178103091
PubChem SID 178103091
Search PubMed clinical trials mogamulizumab
Search PubMed titles mogamulizumab
Search PubMed titles/abstracts mogamulizumab
Wikipedia Mogamulizumab